As does MSB practically every year in some form (a capital raising) and as do all pre-commercial bio-tech companies trying to run labourious and expensive trials. Yawn, play a new record Col, this one is getting worn out. No CYP investors going on MSB threads to bag MSB anymore, you can stop retaliating with unfounded crap....Ross didn't get a golden handshake. If you did the basics of investment, like reading the final share disclosure notices shortly after his departure, you would know that clearly didn't get the pay out you are baselessly trying to tout.
You are better than this Col69.....
Back to the matter at hand, a reasonable cash burn (excluding one offs) and nice to see the Sculptor recruitment rate "has accelerated dramatically during 2023". And that more generally the strategic review pushing a hurry up on trial centres. Ross was too casual with recruitment pressure on the parties involved, nice to see the new lot bringing focus.
For those who missed it:
Investors are invited to join a webcast hosted by Dr Kelly to hear more about the outcomes of the strategic review.
The webcast is scheduled for 9:15am (AEST) on Thursday, 27 July 2023. To pre-register for the event, please follow
this link:
https://ccmediaframe.com/?id=nwqmPZoz.
Upon registration, participants will receive a calendar invitation, details and a link to access the webcast.
(unable to tune in myself due to other commitments)
(20min delay)